Ariella Bar-Gil Shitrit1, Ami Ben Yaʼacov2, Dan Meir Livovsky2, Tzufit Cuker1, Rivka Farkash3, Aviya Hoyda1, Tami Granot1, Irit Avni-Biron4, Adi Lahat5, Eran Goldin2, Sorina Grisaru-Granovsky3. 1. "IBD Mother (MOM)" Unit, Digestive Diseases Institute, Shaare Zedek Medical Center, affiliated with the Medical School, Hebrew University, Jerusalem, Israel. 2. Digestive Diseases Institute, Shaare Zedek Medical Center, affiliated with the Medical School, Hebrew University, Jerusalem, Israel. 3. Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, affiliated with the Medical School, Hebrew University Jerusalem, Israel. 4. Department of Gastroenterology, Rabin Medical Center, Petach Tikva, Israel. 5. Gastroenterology Department, Sheba Medical Center, Ramat Gan, Israel.
Abstract
OBJECTIVES: Despite encouraging data gathered in inflammatory bowel diseases (IBD) patients, Vedolizumabs' (VDZ) safety profile in pregnancy is not established. DESIGN: Data of 330 consecutive pregnancies with IBD was prospectively collected. RESULTS: Women with IBD were treated with: VDZ (n = 24), anti-tumor necrosis factors (n = 82) or conventional therapy (n = 224). Gravidity and parity were similar among the 3 groups. The VDZ group was comprised mostly of Crohn's disease patients who were all not naïve to biological treatment. They had significantly higher conception rates during active disease (P < 0.05), with fewer flares during pregnancy. DISCUSSION: Although further study is needed, VDZ appears of low risk during pregnancy.
OBJECTIVES: Despite encouraging data gathered in inflammatory bowel diseases (IBD) patients, Vedolizumabs' (VDZ) safety profile in pregnancy is not established. DESIGN: Data of 330 consecutive pregnancies with IBD was prospectively collected. RESULTS:Women with IBD were treated with: VDZ (n = 24), anti-tumor necrosis factors (n = 82) or conventional therapy (n = 224). Gravidity and parity were similar among the 3 groups. The VDZ group was comprised mostly of Crohn's diseasepatients who were all not naïve to biological treatment. They had significantly higher conception rates during active disease (P < 0.05), with fewer flares during pregnancy. DISCUSSION: Although further study is needed, VDZ appears of low risk during pregnancy.
Authors: Katarina Mitrova; Barbora Pipek; Martin Bortlik; Ludek Bouchner; Jan Brezina; Tomas Douda; Tomas Drasar; Pavel Drastich; Premysl Falt; Pavel Klvana; Vaclav Leksa; Ales Novotny; Pavel Svoboda; Jan Skorpik; Jan Ulbrych; Marek Veinfurt; Blanka Zborilova; Milan Lukas; Dana Duricova Journal: Therap Adv Gastroenterol Date: 2021-08-07 Impact factor: 4.409
Authors: María Chaparro; María G Donday; Francisco Abad-Santos; Francisco Javier Martín de Carpi; Miguel Ángel Maciá-Martínez; Dolores Montero; Diana Acosta; Yanire Brenes; Javier P Gisbert Journal: Therap Adv Gastroenterol Date: 2021-06-03 Impact factor: 4.409